Ocugen, Inc. - OCGN STOCK NEWS

MALVERN, Pa., Jan. 8, 2021 – Ocugen (NASDAQ: OCGN) announced its participation in upcoming healthcare investment conferences. Dr. Shankar Musunuri, CEO, will present virtually at the CTIC 5th Healthcare Investment Summit (Jan 9-13), H.C. Wainwright BioConnect Conference (Jan 11-14), and Noble Capital Markets 17th Annual Conference (Jan 20). Key topics include the advancement of their modifier gene therapy, biologic product candidate, and COVID-19 vaccine, COVAXIN™, aimed for the U.S. market. The company plans to initiate four Phase 1/2 clinical trials within 1-2 years.

Ocugen, a prominent biopharmaceutical company, has announced the creation of a vaccine scientific advisory board aimed at advancing the clinical and regulatory pathway for COVAXIN™, a COVID-19 vaccine developed in partnership with Bharat Biotech. The board comprises recognized experts from academia and industry, including leaders from Pfizer and the University of Pennsylvania. CEO Dr. Shankar Musunuri expressed enthusiasm about the board’s role in enhancing the vaccine's potential effectiveness and market viability in the US. COVAXIN™ is noted for its unique whole-virion inactivated approach.

Ocugen (NASDAQ: OCGN) announced the adjournment of its 2020 Annual Meeting to provide stockholders more time to vote on Item 2, which proposes amending its certificate of incorporation to reduce the authorized shares of common stock from 500 million to 400 million. The meeting will reconvene on January 13, 2021. Stockholders who have already voted do not need to vote again unless they wish to change their vote regarding Item 2. Voting for other items will remain open until December 23, 2020.

Ocugen (NASDAQ: OCGN) and Bharat Biotech have signed a binding LOI to co-develop the inactivated COVID-19 vaccine candidate, COVAXIN™, for the US market. This collaboration builds on promising Phase 1 and 2 trial results, which involved approximately 1,000 subjects in India. COVAXIN™ is currently in a Phase 3 trial with 26,000 volunteers. Ocugen will manage clinical development, registration, and commercialization in the US. The vaccine aims to provide broad immune coverage against COVID-19.

Ocugen, Inc. (NASDAQ: OCGN) has postponed its 2020 Annual Meeting of Stockholders to December 23, 2020, to allow more time for stockholders to vote on key proposals. The record date for eligible voters remains October 28, 2020. Stockholders who previously submitted proxies do not need to vote again, as their votes will still be valid. Stockholders are encouraged to cast their votes online or by phone before the meeting. The virtual meeting will begin at 11 a.m. Eastern time. For further details, stockholders can visit the company’s official website.

Ocugen, Inc. (NASDAQ: OCGN) will have its CEO, Dr. Shankar Musunuri, speak at Xconomy’s virtual event on December 3, 2020, discussing cell and gene therapies. The panel, moderated by Theresa Lavoie, will cover regulatory and reimbursement roadblocks facing the industry. Ocugen aims to develop transformative therapies for blindness diseases, utilizing a modifier gene therapy platform that treats multiple retinal diseases efficiently. Investors may find interest in the company's innovative approaches as they seek to address underserved diseases.

Ocugen, Inc. (NASDAQ: OCGN) reported its third quarter 2020 results, highlighting progress in its gene therapy developments.

The company is on track to initiate four Phase 1/2a trials in 2021-2022, specifically for its lead candidate OCU400. Ocugen raised approximately $28 million in 2020, enhancing its financial position.

As of September 30, 2020, cash reserves were $19.3 million, a significant increase from $7.6 million at year-end 2019. The company incurred a loss of $0.07 per share, markedly improving from a $3.55 loss per share in 2019.

Ocugen (NASDAQ: OCGN) will present at the Global Chinese Financial Forum Virtual Conference on November 5 at 1:45 PM ET. Dr. Shankar Musunuri, CEO, will discuss the company's innovative modifier gene therapy platform and lead product candidate, OCU400, which targets broad Retinitis Pigmentosa with four FDA orphan drug designations. The presentation will also cover Ocugen's partnership with CanSino Biologics for OCU400 in Greater China and the preclinical development of OCU200 for sight-threatening diseases. Registration for the conference is free.

Ocugen, Inc. (NASDAQ: OCGN) announced that Dr. Shankar Musunuri, CEO and Co-Founder, will present on strategic partnerships in gene therapy at the 4th Annual Gene Therapy for Rare Disorders Europe Conference from October 26-28, 2020. His presentation, titled “The Importance of Strategic Partnerships in Gene Therapy,” is scheduled for October 28 at 11:00 AM GMT. Ocugen focuses on transformative therapies for blindness, leveraging its modifier gene therapy platform to address multiple retinal diseases.